Suicide Attempts Following Fingolimod use in Patients with Relapsing Multiple Sclerosis: Is there a possible link?

  • Shadi Pourmand Multiple Sclerosis Research Center, Neurosciences Institute, Tehran University of Medical Science, Tehran, Iran
  • Mohammad Ali Sahraian Iranian Multiple Sclerosis Society & Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Amir Hossein Pourmand Multiple Sclerosis Research Center, Neurosciences Institute, Tehran University of Medical Science, Tehran, Iran

Abstract

Fingolimod is the first oral therapy approved for reducing exacerbations in Multiple Sclerosis (MS). It is widely accepted that different preparations of beta interferons may aggravate depression and trigger suicide in MS patients and that the drugs should be stopped immediately following the suicidal idea. The association between newly approved drugs such as Fingolimod and Natalizumab with depression and suicidality is not clear. Here, we report three patients with relapsing MS, who committed suicide while receiving Fingolimod. Although the link between suicide and Fingolimod is not clear, but practicing physicians need to be aware of this possible adverse event. It is also important to evaluate the psychological status of the patients not only in patients receiving beta interferons, but also patients who are treated with newly approved drugs.  

Author Biography

Mohammad Ali Sahraian, Iranian Multiple Sclerosis Society & Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Published
2017-01-31
Section
Case Report